Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.
Small Cell Lung Cancer Recurrent
DRUG: Irinotecan Liposome|DRUG: Anlotinib
Objective response rate（ORR）, To evaluate anti-tumor efficacy, From date of first dose until the date of first documented progression, assessed up to 24 months
Disease control rate (DCR), To evaluate anti-tumor efficacy, From date of first dose until the date of first documented progression, assessed up to 24 months|Duration of Response(DoR), To evaluate anti-tumor efficacy, From date of first dose until the date of first documented progression, assessed up to 24 months|Progression-Free Survival (PFS), To evaluate anti-tumor efficacy, From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Overall Survival (OS), To evaluate anti-tumor efficacy, From date of first dose until the date of death from any cause , assessed up to 24 months|Incidence and severity of adverse events, To evaluate the safety, date of the first dose to 28 days after permanent treatment termination
Patients will receive irinotecan liposome injection at 70 mg/m\^2 intravenously, on Days 1 of every 14-day cycle and anlotinib (12 mg/day) for 2 consecutive weeks and then discontinued for 1 week. The treatment is continued until disease progression or intolerable toxicity.